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Background: Farnesoid X receptor (FXR) regulates bile acid (BA) metabolism. High BA levels increase susceptibility to
intestinal tumorigenesis.
Results: caudal-related homeobox 2 (CDX2) directly binds the FXR promoter and regulates FXR expression.
Conclusion: CDX2 transcription factor is a positive regulator of FXR in the gut.
Significance:Manipulation of the APC-CDX2-FXR axis could reduce BA toxicity and intestinal tumor susceptibility.
Farnesoid X receptor (FXR, NR1H4) is a bile acid-activated
transcription factor that belongs to the nuclear receptor super-
family. It is highly expressed in the enterohepatic system, where
it senses bile acid levels to consequently reduce their synthesis
while inducing their detoxification. Bile acids are intestinal
tumor promoters and their concentrations have to be tightly
regulated. Indeed, reduced expression of FXR in the intestine
increases colorectal cancer susceptibility in mice, whereas its
activation can promote apoptosis in genetically modified cells.
Notably, despite the broad knowledge of the FXR enterohepatic
transcriptional activity, the molecular mechanisms regulating
FXR expression in the intestine are still unknown. Herein, by
combining both gain and loss of function approaches and FXR
promoter activity studies, we identified caudal-related homeo-
box 2 (CDX2) transcription factor as a positive regulator of FXR
expression in the enterocytes. Our results provide a putative
novel tool for modulating FXR expression against bile acid-re-
lated colorectal cancer progression.
The epithelium of the small intestine is organized into two
morphologically and functionally distinct compartments:
finger-shaped luminal protrusions termed villi and flask-
shaped submucosal invaginations referred to as the crypt of
Lieberkühn. The villus is a differentiated compartment of
the intestinal epithelium. At the crypt bottom reside stem
cells that self-renew throughout life to generate progenitors
that occupy the lower third of the crypt (1). In the midcrypt
region, cells stop proliferating to differentiate into entero-
cytes. After reaching the epithelial surface, differentiated
cells undergo apoptosis and are shed into the lumen. The
primary driving force of the constant renewal of the gut epi-
thelium is the WNT signaling (1). Thus, mutations of com-
ponents of the WNT pathway have been reported to pro-
mote colorectal cancer (CRC).5 Among these factors, the
APC (adenomatous polyposis coli) gene is believed to be the
gatekeeper in CRC development.
APC is a component of a multiprotein destruction complex
that in the absence of WNT activators sequesters cytoplasmic
-CATENIN to phosphorylate it and targets it for ubiquitin-
proteasome degradation (1). Importantly, while reducing the
activity of -CATENIN, APC also induces the expression of
genes that promote differentiation and cell cycle arrest, such as
P21 (2) and KLF4 (Kru¨ppel-like factor 4) (3). These effects are
mediated by the CDX2 (caudal-related homeobox 2) protein, a
downstream mediator of APC tumor suppressor activity in
intestinal cells (3, 4).
The human CDX2 gene is one of the three mammalian
homologues of theDrosophilahomeobox-containing gene cau-
dal, whose encoded transcription factor has a primary role dur-
ing embryonic development, as assessed by the early lethality of
Cdx2-deficient mouse embryos and the skeleton abnormalities
observed in Cdx2/ (5). During embryogenesis, CDX2 deter-
mines intestinal identity in the presumptive gut endoderm (6,
7), and it is later required to maintain this identity in the intes-
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tinal epithelium throughout adulthood (8). At the molecular
level, it controls the transcription of a huge number of intestinal
genes (9) including KLF4 (3) and P21 (2). CDX2 appears to be
differentially phosphorylated along the crypt-villus axis by the
mitogen-activated protein kinases (MAPK), and thismodulates
CDX2 transcriptional activity and half-life (10–12). The
expression of CDX2 has been found to be altered in human
CRC in relation to the tumor grade (13–15), and its decrease
correlates with poor prognosis (16, 17). Moreover, reduction of
CDX2 expression facilitates tumor progression ofmurinemod-
els of genetically or chemically induced CRC (18, 19). On the
contrary, restoration of CDX2 in colorectal cancer cells has
been shown to reduce cell migration in vitro and dissemination
in vivo (12, 20).
Farnesoid X receptor is an adopted member of the nuclear
receptor (NR) superfamily of transcription factors. Two FXR
(farnesoid X receptor) genes have been identified and are
referred to as FXR (NR1H4) and FXR (NR1H5). FXR is a
pseudogene in humans, whereas it is expressed in rodents, rab-
bits and dogs. It has been proposed to be a lanosterol sensor,
although its physiological function remains to be established
(21). FXR (also referred to FXR) is highly expressed in the
enterohepatic system, where bile acids (BAs) are its endoge-
nous ligands (22–24). FXR encodes four isoforms of tran-
scripts in both humans and mice (FXR1, FXR2, FXR3, and
FXR4) as a result of alternative splicing of exon 5 and the use of
two distinct promoters that initiate transcription from either
exon 1 (5 promoter) or exon 3 (3 promoter) (25, 26). The 5 or
3 promoters of the FXR gene regulate the expression of FXR1
plus FXR2 or FXR3 plus FXR4 transcripts, respectively.
Notably, the four FXR isoforms are expressed in a tissue-spe-
cificmanner along the gut-liver axis, and a few FXR target genes
are regulated in an isoform-dependent manner (26, 27).
By mediating the transcriptional activity of BAs, FXR regu-
lates BAmetabolism. The ability of FXR to reduce BA synthesis
while inducing BA detoxification is of critical importance
because high levels of circulating BA can increase hepatic and
intestinal susceptibility to tumorigenesis (28–31). Notably, the
expression of FXR in the gut is restricted to the differentiated
compartment of the intestinal epithelium (29, 32), and its acti-
vation by BAs will result not only in BA detoxification but also
in increased apoptosis and consequent removal of genetically
modified cells (29, 33). Indeed, the protective role of FXR
against CRC susceptibility has been demonstrated by our group
and others in Fxr knock-out mice, where the first hit for CRC
development was made by inactivating Apcmutations (29, 33).
We also showed that following Apc mutations, the expression
of Fxr was already reduced in aberrant crypt foci of Apcmin//
Fxr/ mice (29). These observations suggest that a down-
streammediator of theApc pathway maymodulate the expres-
sion of Fxr in the intestine.
Although different FXR target genes have been identified in
the intestine, such as FGF19/Fgf15 (fibroblast growth factor
19/15) (34), IBABP (ileal bile acid-binding protein) (35),
OST/ (organic solute transporter /) (36), and those genes
that codify the enzymes involved in BA detoxification (37), the
mechanisms that regulate FXR expression in the intestine are
still unknown.Herein, we identifyCDX2 as a positive transcrip-
tional regulator of intestinal FXR expression. Thus, the manip-
ulation of the APC-CDX2-FXR cascade might be useful in the
future to reduce BA quantity and toxicity fighting against bile
acid-related CRC progression.
EXPERIMENTAL PROCEDURES
Familial Adenomatous Polyposis (FAP) Patients—We ob-
tained tissue samples (tumors and normal intestinal mucosa)
from Dr. R. Valanzano (University of Florence, Florence, Italy)
and Dr. R. Mariani-Costantini (University of Chieti-Pescara,
Chieti, Italy). These unrelated Italian patients with adenoma-
tous polyposis coli were recruited for the study after approval
by the Ethical Committee of the University “G. D’Annunzio” of
Chieti. Written informed consent was obtained from each
patient before mutation analysis and tissue harvesting. All of
the included cases presented with a classic FAP phenotype
and harbored pathogenetic germ line APC mutations (38).
Genomic DNA was isolated from at least two independently
drawn whole blood samples using QIAamp DNA Blood (Qia-
gen, Hilden, Germany). The coding sequence and intron-exon
borders of APC were analyzed by a combination of PCR-based
techniques that included heteroduplex analysis on agarose
minigel for recurring mutations, in vitro synthesized protein
assay of exon 15, single strand conformational polymorphism
analysis of the remaining exons, and denaturing high perform-
ance liquid chromatography (Wave 1100, Transgenomic Inc.,
Omaha, NE) of APC exons 1–15 followed by sequencing. All
mutations were confirmed by sequencing independent PCR
products.
Mice—Heterozygous Cdx2/ mice (5) and relative wild-
type mice were kindly provided by Dr. Jean-Noel Freund.
Apcmin/mice on a pure C57BL/6J background were obtained
from the Jackson Laboratory (Bar Harbor, ME). Cdx2/ and
Apcmin/ and their relative wild-type littermate mice were
housed under pathogen-free conditions and fed a standard
rodent chowdiet in a temperature-controlled room (23 °C) on a
12-h light/dark cycle. Apcmin/ and relative wild-type litter-
mate mice were sacrificed by the age of 6 months, and colon
tumors and adjacent normal areas were harvested. Cdx2/
mice and relative wild-type littermate mice were sacrificed by
the age of 3 months, and small and large intestine were har-
vested. All of the experiments presented in this study have been
carried out inmalemice. The Ethics Committee of the Consor-
zio Mario Negri Sud approved this experimental set-up.
RNA Extraction and qRT-PCR—Animal tissues were snap-
frozen in liquid nitrogen immediately after harvesting and then
stored at80 °Cuntil use. Total RNA from tissues and cells was
isolated by TRIzol reagent (Invitrogen), following the manu-
facturer’s instructions. To avoid possibleDNAcontaminations,
RNA was treated with DNase (Ambion, Austin, TX). RNA
purity was also checked by spectrophotometer, and RNA integ-
ritywas checked by examination on agarose gel electrophoresis.
cDNAwas synthesized, retrotranscribing 4g of total RNA in a
total volume of 100 l using the High Capacity DNA Archive
Kit (Applied Biosystems) and following the manufacturer’s
instructions. To detect mRNA expression levels for the genes
investigated in this study, primers were designed using Primer
Express software spanning intron/exon boundaries whenever
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possible. qPCR assays were performed in 96-well optical reac-
tion plates, using the ABI 7500HT machine (Applied Biosys-
tem). qPCR assays were conducted in triplicate wells for each
sample. The following reactionmixture perwell was used: 10l
of Power SYBRGreen (AppliedBiosystems), 2.4l of primers at
a final concentration of 150 nM, 4.6l of RNase-free water, 3l
of cDNA. For all experiments, the following qPCR conditions
were used: denaturation at 95 °C for 10 min, followed by 40
cycles at 95 °C for 15 s and then at 60 °C for 60 s. Quantitative
normalization of cDNA in each sample was performed using
cyclophilin mRNA as an internal control. Relative quantifica-
tion was done using the CT method, and expression values
have been represented as -fold change between the groups.
Plasmid Constructs—The human CDX2 expression vector
was constructed starting from an ATCC clone containing the
human CDX2 coding sequence, which was PCR-amplified and
subcloned into the pCDNA4B vector using KpnI and BamHI
restriction sites. The region spanning 1195 to 21 in refer-
ence to the transcriptional start sites (TSS) of the human
FXR3/4promoterwas PCR-amplified fromgenomicDNAof
HT29 cells. The quality of the PCR products was checked by
sequencing. PCR product was then inserted upstream of the
firefly luciferase gene in the multiple-cloning site of the pro-
moterless vector pGL3-basic (Promega), using SacI/NheI
restriction sites to create pGL3-FXR3/4-luc(1195/21)
reporter construct. The numbers in parenthesis indicate the
nucleotide positions with respect to the TSS. Starting from
the pGL3-FXR3/4-luc(1195/21) plasmid, deletion frag-
ments containing putativeCDX2 binding sites (ATAAA, sense;
TATTT, antisense) were subcloned into the promoterless vec-
tor pGL3-basic using SacI/NheI restriction sites to generate the
reporter constructs pGL3-FXR3/4-luc(724/21), pGL3-
FXR3/4-luc(376/21), pGL3-FXR3/4-luc(118/21),
pGL3-FXR3/4-luc(64/21). Twomutant reporter vectors
were generated from the pGL3-FXR3/4-luc(118/21) and
pGL3-FXR3/4-luc(1195/21) plasmid, respectively, using
a site-directed mutagenesis kit (QuikChange, Stratagene, La
Jolla, CA). Site-directed mutagenesis of the putative CDX2
binding site was introduced by substitution of the underlined
nucleotides in the sequence ATAAA to obtain the AGCAA
sequence.
Adenovirus Constructs—CDX2 adenovirus (AdCDX2) was
generated using the Viral Power Adenoviral Expression System
(Invitrogen). Briefly, the human CDX2 coding sequence was
PCR-amplified and subcloned from the pCDNA4B-CDX2plas-
mid into the pENTR4 shuttle vector using SalI andXhoI restric-
tion sites. Then pENTR4-CDX2 plasmid was recombined with
the destination vector pAd/CMV/V5-DEST to generate an
adenovector containing human CDX2 under the control of the
human cytomegalovirus promoter. The adenovector coding
-galactosidase under the control of the human cytomegalovi-
rus promoter (pAd/CMV/V5-GW/LacZ) was purchased from
Invitrogen. Short hairpin CDX2 adenovirus (AdshCDX2) was
generated based on a previously validated sequence against
human CDX2 (39) using the BLOCK-iT U6 RNA entry vector
kit (Invitrogen). Short hairpin CDX2 oligonucleotides were
synthesized with complementary ends to be subcloned into the
pENTR/U6 shuttle vector. Then the pENTR/U6-shCDX2 plas-
mid was recombined with the destination vector pAd/BLOCK-
iT-DEST to generate an adenovector containing short hairpin
CDX2 under the control of the U6 promoter. The oligonucleo-
tides to generate the adenovector control AdshLacZ were pur-
chased from Invitrogen. Indeed, AdshLacZ was constructed
with the same procedure used to make AdshCDX2. AdCDX2,
AdLacZ, AdshCDX2, and AdshLacZ vectors were linearized
with PacI restriction enzyme, and 1 g of digested products,
after purification with the Qiaex II gel extraction kit (Qiagen),
were used to transfect 5 105 293A cells (Invitrogen) with 3l
of Lipofectamine 2000 (Invitrogen) to generate the correspond-
ing adenoviruses. The viruses were propagated into 293A cells.
Crude viral lysate stocks were stored at 80 °C until use. The
adenoviral titer was determined by qRT-PCR with specific
primers (40).
Cell Cultures, Treatments, and Adenovirus Transduction—
HT29, Caco2, HeLa, and 293A cells were maintained in Dul-
becco’s modified Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum and 1% antibiotic. LS174T were main-
tained in RPMI medium supplemented with 10% fetal bovine
serum and 1% antibiotic. HT29 differentiation was achieved
by postconfluence and sodium butyrate (NaBt) treatment.
Regarding postconfluence-induced differentiation, 5  104
cells/well were seeded in a 6-well plate. Cells were harvested at
day 3 (preconfluence), day 7 (confluence), and day 14 (postcon-
fluence) after seeding. RegardingNaBt-induced differentiation,
5 104 cells/well were seeded in a 6-well plate and treated with
NaBt 1 mM for 48 h. Caco2 differentiation was achieved by
supplementing cells with 20% fetal bovine serum after conflu-
ence. Cells were harvested at days 4, 8, and 15 after confluence.
HT29 and LS174T were transduced with a 100 multiplicity of
infection (MOI) of AdCDX2 or control AdLaZ for 48 h. For the
functional study, 48 h after transduction, HT29 cells were
treated for 24 h with 1 M GW4064. For the NaBt-induced
differentiation study, HT29 cells were first transducedwith 200
MOI of AdshCDX2 or control AdshLacZ and then 24 h after
transduction, cells were treated for 48 h with 1 mM NaBt.
Transient Transfections andLuciferaseAssays—For the lucif-
erase assays, HeLa cells, at 70% of confluence, were seeded in
12-well plates for 24 h. The next day, 1 h before transfection,
complete DMEM was aspirated, cells were washed twice with
warm PBS, and 1 ml of DMEM free of antibiotic was added to
each well. Indeed, cells were co-transfected using Lipo-
fectamine 2000 (Invitrogen) following the manufacturer’s
instructions. Briefly, for the deletion and mutagenesis experi-
ments, cells were co-transfected using 10 l of Lipofectamine
2000 with 2 g of pCDNA4B (control) or pCDNA4B-CDX2
expression vector, 1g of pGL3-basic or pGL3-FXR3/4 pro-
moter constructs, and 0.1g of Renilla reporter plasmid (pRT-
TK). 24 h after transfection, cells were lysed, and luciferase
activity was measured with the Dual Luciferase Reporter Assay
system (Promega) according to the manufacturer’s instruc-
tions. Results were expressed as -fold over pGL3 activation. To
investigate the effect ofmutantCDX2 on the ability ofwild-type
CDX2 to transactivate the FXR3/4 promoter, HeLa cells
were co-transfectedwith 1mg of pGL3-FXR3/4-luc(1995/
21), 2 g of wild-type CDX2, and increasing amounts of
mutant CDX2. The total amount of DNA was kept constant at
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15g by the addition of pCDNA4B plasmid. The relative firefly
luciferase activitieswere calculated by normalizing transfection
efficiency according to the Renilla luciferase activities. All
experiments were performed in triplicate, and similar results
were obtained from at least three independent experiments.
Histology and Immunohistochemistry—Tissue specimens
were fixed in 10% formalin for 12–24 h, dehydrated, and paraf-
fin-embedded. Standard histology (H&E) and immunohisto-
chemical procedures were performed. Briefly, with respect to
immunohistochemistry, 5-m-thick sectionswere treatedwith
3% hydrogen peroxide for 5min, to quench endogenous perox-
idase and subjected to antigen retrieval by boiling the slides in
antigen unmasking solution (Vector Laboratories Inc., Burlin-
game, CA) for 15 min according to the manufacturer’s instruc-
tions. Sectionswere sequentially incubated for 1 h at room tem-
perature in 50% non-immune serum (from the host animal in
which the secondary antibody was raised) in PBS (to avoid
nonspecific signal) and overnight at 4 °C with the primary anti-
bodies (FXR antibody was a generous gift from Phenex Phar-
maceutical AG; CDX2 antibody was purchased from Zymed
Laboratories, Inc. (San Francisco, CA)). Sections were washed
for 10 min in PBS and incubated for 30 min at room tempera-
ture with the secondary biotinylated antibody (Vector Labora-
tories). After several washing steps with PBS (three washes, 5
min each), sections were incubated with the avidin-biotin com-
plex (Vector Laboratories) for 30 min at room temperature.
After washing in PBS, the peroxidase reactionwas developed by
incubation with 3,3-diaminobenzidine (Sigma-Aldrich). Coun-
terstaining was carried out with methylene blue (Sigma-Al-
drich). For negative controls, 1% non-immune serum in PBS
replaced the primary antibodies.
Western Blot—Cells were lysed with radioimmune precipita-
tion buffer (150 mM NaCl, 1.0% Igepal CA-630, 0.5% sodium
deoxycholate, 0.1% SDS, 50mMTris, pH 8.0; Sigma) containing
protease inhibitors (Roche Applied Science). Cells lysed were
cleared by centrifugation at 12,000 rpm for 10 min. Protein
concentration was determined by DC protein assay reagent
(Bio-Rad). Protein lysates (50g/sample) were heated at 100 °C
for 5 min in Laemmli buffer (60 mM Tris, pH 6.8, 10% glycerol,
2% SDS, 5%-mercaptoethanol, and 0.005%bromphenol blue).
Proteins were isolated by 7.5% SDS-polyacrylamide gel electro-
phoresis and transferred to polyvinylidene difluoride (PVDF)
membranes (Amersham Biosciences). The membranes were
blocked with a blocking buffer and then incubated at room
temperature for 2 h with antibodies against FXR (a gift from
Phenex Pharmaceutical AG) and CDX2 (Zymed Laboratories,
Inc.). The membranes were extensively washed with PBS, 20%
Tween and then incubated at room temperature for 1 h with a
horseradish peroxidase-labeled anti-rabbit IgG for FXRor anti-
mouse IgG for CDX2. The immune complexes were visualized
with the use of Super Signal ECL Plus (Amersham Biosciences)
according to the manufacturer’s protocol.
Alkaline Phosphatase Measurement—NaBt-treated HT29
cells and preconfluent, confluent, and postconfluent HT29 and
Caco2 cells were scraped from 6-well plates in ice-cold PBS and
then centrifuged for 5min at 3000 rpm at 4 °C. Supernatant was
discarded, and pellet was resuspended in 200 l of lysis buffer
made by 80% radioimmune precipitation buffer (50 mM Tris-
HCl, pH 8.0, with 150mM sodium chloride, 1.0% Igepal CA-630
(Nonidet P-40), 0.5% sodium deoxycholate, 0.1% SDS; Sigma)
and 20% protease inhibitors (Roche Applied Science). After 15
min in ice, sampleswere centrifuged for 10min at 12,000 rpmat
4 °C. Then 20 l of supernatant was added to 100 l of alkaline
phosphatase reagent (Sigma), and the absorbance was mea-
sured at 504 nm after a 30-min incubation at 37 °C. Alkaline
phosphatase levels were corrected with total proteins, whose
levels were evaluated by DC protein assay reagent.
Electrophoretic Mobility Shift Assay—Nuclear extracts were
prepared from HeLa cells transduced with 100 MOI of
AdCDX2. Cells were harvested 48 h after transduction by
scraping and then resuspended in cold Tris-buffered saline (pH
7.4), followed by centrifugation at 4000 rpm for 2 min. Cells
were resuspended in 100 l of buffer A (10 mmol/liter HEPES,
pH 7.9, 1.5 mmol/liter MgCl2, 10 mmol/liter KCl, and 0.5
mmol/liter phenylmethylsulphonyl fluoride) and incubated on
ice for 15 min. After the addition of 4 l of 10% Triton X-100,
samples were vortexed for 10 s and centrifuged at 13,000 rpm
for 2min. Pellets were resuspended in 50l of cold buffer C (20
mmol/liter HEPES, pH 7.9, 1.5 mmol/liter MgCl2, 0.4 mol/liter
NaCl, 0.2 mmol/liter EDTA, 25% glycerol, 0.2 mmol/liter DTT,
and 0.5 mmol/liter phenylmethylsulphonyl fluoride) and incu-
bated on ice for 30 min. Protein concentrations in nuclear
extracts were 0.5–1 mg/ml, as determined by the Bradford
method. The sense and antisense oligonucleotides containing
the CDX2-binding sites were annealed with a complementary
primer and radiolabeled with [32P]dCTP (Amersham Biosci-
ences). The labeled probeswere purified by size exclusion chro-
matography through a 0.5-ml column of Sephadex G-25
(Amersham Biosciences). Nuclear extracts (5 g) were incu-
bated with radiolabeled DNA probes (1 105 cpm) for 20 min
at room temperature in 18 l of binding buffer containing 60
mmol/liter HEPES, 180 mmol/liter KCl, 3 mmol/liter EDTA,
36% glycerol, 15mmol/liter DTT, and 4g of poly(dI-dC). Pro-
tein-DNA complexes were separated from free DNA probes by
electrophoresis through 5% non-denaturing acrylamide gels in
5 TBE buffer. Gels were dried under vacuum on filter paper
and exposed for 16–40 h to Eastman Kodak Co. XAR film at
80 °C for autoradiograph detection. Specificity of bindingwas
ascertained by competition with excess cold consensus
oligonucleotides.
Chromatin Immunoprecipitation (ChIP)—HCT116 cells
were transfected with pFLAG-CMV2 (Sigma) or pFLAG-
CMV2-hCdx2 (41) using JetPrime (Polyplus transfection) as
recommended (1  106 cells in 3.5-cm plates: 2.4 g of total
DNA and 4.8 l of JetPrime in 250 l of JetPrime buffer). After
48 h, transfected cellswere fixedwith 1% (v/v) formaldehyde for
10min at room temperature and quenchedwith 0.125M glycine
for 5 min. ChIP experiments were carried out using the Magna
ChIPTM G chromatin immunoprecipitation kit as recom-
mended by the supplier (Millipore). Sheared cross-linked chro-
matin from 106 cells was incubated overnight at 4 °C with 2
g of normal mouse IgG (Santa Cruz Biotechnology, Inc.) or
mouse anti-FLAG (clone M2, Sigma) antibody. Input corre-
sponded to non-immunoprecipitated sheared cross-linked
chromatin from 105 cells (1%). qPCR analyses were per-
formed with one-twenty-fifth of the immunoprecipitated DNA
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as template using SYBR Green Master Mix in a 7500Fast PCR
detection system (Applied Biosystem). Primers are located in
the human FXR promoter (forward, GAGCCAGTGAACA-
GAAACCC; reverse, AGTGAGAGAGGACAGAGGTTG).
Statistical Analysis—All results are expressed asmean S.E.
Data distribution and gene expression statistical analysis were
performed using NCSS statistical and power analysis software
2007 (Kaysville, UT). Multiple groups were tested by one-way
analysis of variance or two-way analysis of variance repeated
measures where appropriate, followed by Fisher’s least signifi-
cant difference test for unpaired data. Comparisons of two
groups were performed using Student’s t test, followed by a
Mann-WhitneyU test where appropriate. p	 0.05 was consid-
ered significant.
RESULTS
Inactivating APC Mutations Result in Both CDX2 and FXR
Reduced Intestinal Expression—CDX2 is a downstream media-
tor ofAPC, and because most colorectal tumors present inacti-
vating mutations of APC protein (42) that result in decreased
expression and activity of CDX2 (3, 4), the link between CDX2
and FXR expression was first investigated in the context of
APC-dependent tumors. To this end, we used samples of
Apcmin/ mice and FAP patients. Immunohistochemical anal-
ysis of colon sections from Apcmin/mice confirmed the paral-
lel reduced expression of Cdx2 and Fxr also at the protein level
when comparing tumors with normal adjacent regions (Fig.
1A). Also, in the colon of both models of intestinal tumorigen-
esis, the expression of CDX2 and FXR1/2 as well as
FXR3/4 was significantly reduced at the mRNA level when
compared with normal adjacent areas (Fig. 1, B and C). Inter-
estingly, at support of the idea that CDX2 might regulate FXR
expression, human differentiated colorectal tumor that
retained a certain expression ofCDX2 also presented a remark-
able FXR expression (Fig. 1D).
The Intestinal Expression of FXR Is Reduced in Cdx2/
Mice—To further corroborate our hypothesis that CDX2 regu-
lates FXR expression in vivo, we assessed mRNA and protein
FIGURE 1. Intestinal down-regulation of CDX2 and FXR expression after inactivating APC mutations. A, paraffin-embedded specimens from normal
colonic mucosa and colon tumors of Apcmin/mice were immunostained with Cdx2 and Fxr antibodies to determine expression and localization of CDX2 and
FXR proteins in normal tissue and tumors (200magnification). B, qRT-PCRwas used to investigate the relative expression of Cdx2, Fxr1/2, and Fxr3/4 in
tumor samples and adjacent normal areas from the colon of Apcmin/ mice. Values shown represent -fold change  S.E. (error bars) (p 	 0.05) for five
independent determinations performed in duplicate. Cyclophilin was used as a housekeeping gene to normalize data, and normal samples were used as a
calibrator. C, qRT-PCR was used to investigate the relative expression of CDX2, FXR1/2, FXR3/4 in colon tumors from five FAP patients. Values shown are
-fold decrease of mRNA levels in colon tumors relative to normal adjacent tissue. Cyclophilin was used as a housekeeping gene to normalize data. D,
immunohistochemical analysis of sections of human colorectal tumors with certain CDX2 expression. Shown are representative fields of sections of human
colon tumors stained with CDX2 and FXR antibodies (200 magnification).
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levels of Fxr in Cdx2/ mice. Indeed, immunohistochemical
analysis of morphologically normal colon sections from
Cdx2/ mice revealed a consequent reduced expression of
Cdx2 and Fxr (Fig. 2A). This result was confirmed at themRNA
level, where both Fxr1/2 and Fxr3/4 isoforms displayed a
reduced expression inCdx2/mice compared with littermate
wild-type mice (Fig. 2B). Notably, the same results were
obtained for the small intestine, with an even more significant
reduction of Fxr expression (Fig. 2C). Overall, our findings sug-
gest that FXR expression in the intestinal mucosa is directly
proportional to Cdx2 allelic quantity.
FXR Expression Correlates with Increased CDX2 Expression
during Enterocyte Differentiation—APC gains a gradient of
expression along the crypt-villus axis with lower expression in
the proliferative compartment and higher expression in the dif-
ferentiated compartment. Indeed,CDX2, which is expressed all
along the crypt-villus axis, is mainly active in differentiating
enterocytes (9, 11, 43), where it induces the transcription of
several genes associated with differentiation of the intestinal
epithelium. In line with these observations, several in vitro
studies have reported that overexpression of CDX2 in gut epi-
thelial cells leads to growth arrest accompanied by up-regula-
tion of severalmarkers associatedwith intestinal differentiation
(44, 45). Because FXR is also expressed in the differentiated
compartment of the intestinal epithelium (Fig. 1A), we investi-
gated whether the expression of FXR follows that ofCDX2 dur-
ing differentiation.
In vitro cell culture experiments have shown that cell-to-cell
contact can trigger both cell cycle exit and induction of the
differentiation process (46). To investigate the correlation
betweenCDX2 and FXR expression during enterocyte differen-
tiation, we used colorectal cancer HT29 cells, which showmor-
FIGURE2. Intestinal FXRexpression is reduced inCdx2/mice.A, paraffin-embeddedspecimens fromnormal colonicmucosaofCdx2/miceand relative
littermate wild-type mice were immunostained with CDX2 and FXR antibodies to determine expression and localization of CDX2 and FXR proteins (200
magnification). B, qRT-PCR was used to investigate relative mRNA levels of Cdx2, Fxr1/2, and Fxr3/4 in the colon of Cdx2/mice and relative littermate
wild-typemice. Values shown represent -fold change S.E. (error bars) (p	 0.05) for five independent determinations performed in duplicate. Cyclophilinwas
used as a housekeeping gene to normalize data, andwild-typemicewere used as a calibrator.C, qRT-PCRwas used to investigate relativemRNA levels ofCdx2,
Fxr1/2, and Fxr3/4 in the ileum of Cdx2/mice and relative littermate wild-type mice. Values shown represent -fold change S.E. (p	 0.05) for five
independent determinations performed in duplicate. Cyclophilin was used as a housekeeping gene to normalize data, and wild-type mice were used as a
calibrator.
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phological features of enterocyte differentiation when main-
tained in the confluence state. In contrast, in colon tumor
specimens with APCmutations (Fig. 1,A and B), we noticed an
increased FXR expression (mainly FXR3/4) over time along
with that of CDX2 at the mRNA level (Fig. 3A). These results
were also confirmed in Caco2 cells, which are widely used to
study the intestinal differentiation process in vitro (data not
shown). In support of our model of intestinal differentiation
in vitro, we observed an increase of alkaline phosphatase
(ALP) activity from pre- to postconfluence state (Fig. 3B).
Indeed, ALP is a well established marker of intestinal differ-
entiation, which is expressed by differentiated but not by
undifferentiated enterocytes.
In addition to differentiation induced by cell-to-cell contact,
we also investigated a chemicalmodel of differentiation.NaBt is
a short-chain fatty acid formed in the gastrointestinal tract of
mammals as a result of anaerobic bacterial fermentation of
soluble dietary fibers and is avidly absorbed by the colonic epi-
thelium. In vitro studies have indicated that NaBt induces dif-
ferentiation and apoptosis, effects that might mediate the pro-
tective role of dietary fibers against CRC. Treatment of HT29
cells with NaBt at 1 mM concentration was able to induce the
expression ofCDX2 and FXR (mainly FXR3/4) at themRNA
level (Fig. 3C). Again, differentiation was confirmed by the
increased levels of ALP following NaBt treatment (Fig. 3D).
To further confirm that the inductionofFXR expressionduring
enterocyte differentiation is dependent on CDX2 activity, HT29
cellswere first transducedwithAdshCDX2orAdshLacZand then
treated with NaBt to induce differentiation. As shown in Fig. 3E,
treatment with NaBt was able to induce FXR3/4 expression
only in the presence of AdshLacZ and not in the presence of
AdshCDX2. These data demonstrate that CDX2 is required to
induce FXR expression during enterocyte maturation.
Functional Induction of FXR in the Enterocytes via CDX2—
To further demonstrate that CDX2 induces FXR expression,
HT29 cells were transduced with AdCDX2 or control AdLacZ.
Ectopic expression of CDX2 resulted in higher mRNA levels
of FXR3/4 and also FXR1/2 (Fig. 4A). KLF4 and P21
and CDX2 target genes, were also induced by CDX2 trans-
duction. Interestingly, the same results were obtained in
LS174T cells, which do not differentiate into enterocytes
(Fig. 4B). Because HT29 cells have a mutated form of APC
but a wild type -CATENIN, whereas LS174T cells have a
wild type APC but a mutated -CATENIN, these results
FIGURE 3. Correlation between CDX2 and FXR expression during in vitro confluence- and NaBt-induced differentiation. A, relative mRNA levels of
FXR1/2, FXR3/4, and CDX2 in HT29 cells (preconfluence, confluence, and postconfluence) were investigated by real-time qPCR. Values shown represent
-fold change S.E. (error bars) of four independent determinations performed induplicate. Cyclophilinwas used as housekeepinggene tonormalize data, and
preconfluent cells were used as calibrators. Different lowercase letters indicate significant difference (p 	 0.05). B, ALP activity was analyzed as marker of
differentiation in HT29 cells from pre- to postconfluence. Values shown represent mean S.E. (p	 0.05) for four independent determinations performed in
duplicate andwere normalized to total mg of proteins. C, relativemRNA levels of CDX2, FXR1/2, and FXR3/4 in HT29 cells treatedwith 1mMNaBt for 24 h.
Values shown represent -fold change  S.E. of four independent determinations performed in duplicate. Cyclophilin was used as a housekeeping gene to
normalize data, and vehicle-treated cellswere used as calibrators.D, ALP activitywas analyzed asmarker of differentiation inHT29 cells treatedwithNaBt 1mM
for 48 h. Values shown represent mean  S.E. (p 	 0.05) for four independent determinations performed in duplicate and were normalized to total mg of
proteins. E, down-regulation ofCDX2during enterocyteNaBt-induceddifferentiation impairs FXRup-regulation. HT29 cells were first transducedwith 200MOI
ofAdshCDX2orAdshLacZand then, 24hafter adenovirus transduction, treatedwith1mMNaBt.CDX2, FXR1/2, and FXR3/4mRNA levelswere investigated
48 h after NaBt treatment. Values shown represent -fold change S.E. (p	 0.05) of four independent determinations performed in duplicate. Cyclophilin was
used as a housekeeping gene to normalize data, and AdshLacZ transduced cells were used as calibrators.
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underline the independence ofCDX2 transcriptional activity
from the cytoplasmic APC and nuclear -CATENIN-TCF-4
status of the cell.
To investigate whether the induction of FXR by CDX2 was
also functional, HT29 cells were first transducedwith AdCDX2
or AdLAcZ and then treated with GW4064, a selective FXR
ligand.As shown in Fig. 4C, treatmentwithGW4064 resulted in
further induction of FGF19 and IBABP (FXR target genes) after
AdCDX2 transduction. These results indicate that CDX2
induction of FXR expression is coupled with augmented FXR
transcriptional activation in response to ligand.
In Silico Analysis of FXR Promoters—To identify new candi-
dates for the transcriptional regulation of FXR in the intestine,
in silico analysis of both FXR promoters until 3000 bp from
their relative TSS was performed using the Mat Inspector soft-
ware (Genomatix). In particular, we focused on transcription
factors that are both specifically expressed in the intestine and
under the control of APC. Thus, we found several TTTAT
(sense) or ATAAA (antisense) motifs that have been shown to
bind to CDX2, a downstreammediator of APC, which is exclu-
sively expressed in the gut.
CDX2 Is a Direct Transcriptional Activator of FXR3/4
Promoter—Following our in silico analysis, both FXR1/2 and
FXR3/4 promoter regions were cloned into the pGL3-luc
basic vector to evaluate whether FXR is a transcriptional direct
target of CDX2 by a reporter assay. Indeed, FXR-luc reporter
FIGURE 4. Functional induction of FXR by CDX2. A, HT29 cells were transduced with 100MOI of AdCDX2 or AdLacZ, and relativemRNA levels of CDX2, KLF4,
P21, FXR1/2, and FXR3/4were investigated by qRT-PCR after 48 h. Values shown represent -fold change S.E. (error bars) (p	 0.05) for four independent
determinations performed in duplicate. Cyclophilin was used as a housekeeping gene to normalize data, and AdLacZ-transduced cells were used as a
calibrator.Different lowercase letters indicate significant difference (p	 0.05). B, LS174T cells were transducedwith 100MOI of AdCDX2 or AdLacZ, and relative
mRNA levels of CDX2, KLF4, P21, FXR1/2, and FXR3/4were investigated by qRT-PCR after 48 h. Values shown represent -fold change S.E. (p	 0.05) for
four independent determinations performed in duplicate. Cyclophilinwas used as a housekeeping gene to normalize data, andAdLacZ-transduced cells were
used as a calibrator. Different lowercase letters indicate significant difference (p	 0.05). C, 48 h after AdCDX2 or AdLacZ transduction, HT29 cells were treated
with 1MGW4064 for 24h, and the expressionof two FXR target genes (FGF19 and IBABP)was investigated. Values shown represent -fold change S.E. for four
independent determinations performed in duplicate. Cyclophilin was used as a housekeeping gene to normalize data, and AdLacZ-transduced cells treated
with vehicle were used as calibrator. Different lowercase letters indicate significant difference (p	 0.05).
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constructs and pCDNA4B-CDX2 expression vector were co-
transfected into HeLa cells, which lack endogenous CDX2.
With respect to FXR1/2, although we cloned until3000 bp
from its TSS, CDX2 was not able to trans-activate this pro-
moter. On the other hand, when the FXR3/4-luc(1195/
21) reporter alongwith pCDN4B-CDX2were co-transfected,
CDX2 was able to trans-activate the FXR3/4 promoter (Fig.
5A). These data suggest that CDX2 might regulate directly
FIGURE 5.CDX2 is a direct transcriptional activator of FXR3/4promoter. A, structure of the pGL3-FXR3/4-luc plasmid is shown. The pGL3-FXR3/4-
luc(1195/21), pGL3-FXR3/4-luc(724/21), pGL3-FXR3/4-luc(376/21), pGL3-FXR3/4-luc(118/21), and pGL3-FXR3/4-luc(64/21)
plasmids contain the 1195-, 724-, 376-, 118-, and 64-bp fragments, respectively, of the human FXR3/4 gene promoter plus the first 21 bp of exon 3 linked to
a luciferase reporter. Seven putative CDX2 binding sites are shown. Luciferase activity was measured in response to expression of CDX2 in HeLa cells co-
transfectedwith thepRL-TKRenilla luciferase reporter and thedifferent pGL3-FXR3/4-luc plasmids. Resultswere normalized toRenilla luciferase activity and
expressed as -fold over pGL3-basic activation. Values are expressed as themeans S.E. (error bars) of triplicate cultures (p	 0.05). B, HeLa cells after transient
co-transfection ofCDX2or relative empty vector (pCDNA4B), pGL3-FXR3/4-luc(118/21), andpGL3-FXR3/4-luc(1195/21) reporters (WT) or relative
mutated plasmids for the candidate CDX2 binding site (mut). Results were normalized to Renilla luciferase activity and expressed as -fold over pGL3-basic
activation. The results are expressed as the means  S.E. of triplicate cultures (p 	 0.05). C, the effect of mutant CDX2 on the ability of wild-type CDX2 to
transactivate FXR3/4 promoter. HeLa cells were co-transfected with pGL3-FXR3/4-luc(1195/21), pRL-TK Renilla luciferase reporter, pCDNA4B, and
either wild-type CDX2 alone, wild-type CDX2with increasing amounts of mutant CDX2, or mutant CDX2 alone. The total amount of DNA transfected was kept
constant at 15g. The ratio of firefly luciferase activity to control Renilla luciferase activity is indicated (in arbitrary units). All experiments are expressed as the
means S.E. of triplicate cultures. Different lowercase letters, significant statistical difference (p	 0.05). D, EMSA shows physical interaction between CDX2
protein and FXR3/4promoter. Synthetic oligonucleotides containing theputativeCDX2binding site between118 and21on the FXR3/4promoter are
reported under “Results.” Nuclear extract (5g) fromHeLa cells transducedwith AdCDX2was incubatedwith the 32P-labeled FXRoligonucleotide probe alone
(lane 2) and in thepresence of 50, 100, or 500unlabeled FXR competitor oligonucleotides (lanes 3–5). In lane 1, only 32P-labeled FXRoligonucleotidewas added.
Sampleswere loaded on a 5%acrylamide gel. E, binding of CDX2 to the regulatory region of FXRwas confirmedby ChIP-qPCR in theHT116 cell line transfected
with pFLAG-CMV-2-hCDX2 plasmid. Results are shown as enrichment of FXR promoter relative to empty vector. We used normal IgG as negative control. Bar
plots, mean S.E. of two independent experiments. The significance of difference was determined by Student’s paired t test.
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FXR3/4 and indirectly FXR1/2. To better characterize the
putative CDX2 binding sites in this region of the FXR3/4
promoter, we generated a series of reporters, including a pro-
gressively decreasing number of the putative binding sites of
CDX2 (Fig. 5A). As a result, deletions of putativeCDX2 binding
sites on the 5 side from1195 to118 did not affect the ability
of CDX2 to transactivate this promoter, suggesting that the
putative CDX2 binding site closer to the TSS is crucial for
CDX2 to transactivate the FXR3/4 promoter. Indeed, in situ
mutagenesis of this putative CDX2 binding site abrogated the
ability of CDX2 to transactivate the FXR3/4 promoter (Fig.
5B). These results clearly demonstrate that the sequence
between 118 and 64 has a key role in inducing FXR3/4
expression via CDX2. The role of CDX2 in transactivating the
FXR3/4 promoter has been further confirmed in a competi-
tion study where HeLa cells were co-transfected with the
FXR3/4-luc(1195/21) reporter and increasing ratios of
mutant devoid of transcriptional activity over wild-type CDX2.
In the presence of mutant CDX2, the ability of wild-type CDX2
to transactivate the FXR3/4 promoter was dramatically
reduced (Fig. 5C), underlining that a wild-type form ofCDX2 is
required to induce FXR3/4 expression.
Finally, to examine the physical interaction between
FXR3/4promoter andCDX2homeodomain protein, we per-
formed an EMSA. The oligonucleotide sequences used in this
study were CTTTCCTCATAAACATTTACA (forward) and
TGTAAATGTTTATGAGGAAAG (reverse). They were cho-
sen on the base of the deletion mutant analysis, indicating that
the portion from 118 to 64 contains the genuine CDX2
binding site. These sequences were labeled, incubated in the
presence of nuclear extract from HeLa cells transduced with
AdCDX2, and then migrated through a 5% non-denaturating
polyacrylamide gel. The autoradiograph in Fig. 5D reveals the
position of rapidly migrating unbound probes at the base of the
gel and several DNA-protein complexes of slowermobility that
were formed after incubation with the HeLa nuclear extract
(lane 2), whereas no band shift occurred in lane 1, in which no
nuclear extract was added. The specificity of DNA/CDX2 pro-
tein complexes was ascertained by competition with a 50–500-
fold excess of cold oligonucleotides (lanes 3–5). These results
indicate that CDX2 interacts physically with the FXR3/4
promoter. In order to further demonstrate that FXR is a CDX2
target gene, we performed chromatin immunoprecipitation
(ChIP) experiments in HT116, a colon cancer cell line. We
observed a significant enrichment of FXR promoter inHCT116
cell line transfected with pFLAG-CMV-2-hCDX2 over empty
vector as well as negative controls as IgG (Fig. 5E). These data
show the direct binding of CDX2 on the FXR promoter in vivo,
thus further supporting the hypothesis that CDX2 regulates
FXR expression in the gut.
DISCUSSION
FXR is highly expressed in the enterohepatic system, where
BAs, which are its endogenous ligands, circulate. Upon activa-
tion by BAs, FXR is engaged in many molecular pathways for
themanagement of BAhomeostasis, including reduced synthe-
sis and increased detoxification. Indeed, physiological FXR
expression and function is required not only to preserve BA
homeostasis but also to temper their deleterious effects in the
enterohepatic system, as shown in Fxr-null mice (28–31, 47).
Activation of FXR can induce the orphan nuclear receptor SHP
(small heterodimer partner) (48) and FGF19/Fgf15 (49) expres-
sion in the liver and intestine, respectively, to synergistically
reduce BA synthesis. At the same time, activation of FXR in the
enterohepatic system induces CYP3A4/Cyp3a11 (cytochrome
P450 3A4/3a11), SULT2A1 (cytosolic sulfotransferase 2A1),
and UGT2B4 (UDP-glycosyltransferase 2B4) to induce BA
detoxification (37).
Although different FXR target genes important to deal with
BA levels have been identified in the enterohepatic system, so
far themolecularmechanisms regulating FXR expression in the
intestine have remained unknown. In the present study, we
shed light on this issue, showing that CDX2 positively regulates
FXR expression in the intestine. Because we previously showed
that upon inactivating theAPCmutation, the intestinal expres-
sion of FXR is dramatically reduced (29), we focused on a tran-
scriptional downstream mediator of APC activity that was co-
expressed with FXR in the differentiated compartment of the
intestinal epithelium. Our analysis revealed several putative
binding sites for CDX2 in both FXR1/2 and FXR3/4 pro-
moters. Because ofAPC induces the expression ofCDX2 (4), we
found that the expression of both FXR1/2 and FXR3/4
was reduced not only inApcmin/mice but also in FAP patients.
Additional data indicating that FXR is a target gene of CDX2
were obtained in Cdx2/mice, where the reduced expression
of Cdx2 proceeded with the decreased mRNA levels of both
Fxr1/2 and Fxr3/4. The correlation between CDX2 and
FXR expression was also confirmed in an in vitro model of
enterocyte differentiation. During the confluence- or NaBt-in-
duced differentiation of HT29 and Caco2 cells, the expression
of FXR (mainly FXR3/4) resulted increased along with
CDX2. As support of the role of CDX2 in inducing the expres-
sion of FXR during differentiation, knocking down CDX2 dur-
ing NaBt treatment resulted in a lack of FXR induction. More-
over, infection with AdCDX2 of HT29 cells and LS174 cells
resulted in overexpression of FXR (mainly FXR3/4). Inter-
estingly, the induction of FXR by CDX2 was also functional
because treatment with GW4064 resulted in up-regulation
of FXR target genes, such as FGF19 and IBABP. Finally, a
reporter and EMSA assay along with ChIP experiments on the
FXR3/4 promoter demonstrated a direct regulation of
FXR3/4 by CDX2. With regard to FXR1/2, we could not
show a direct regulation of its promoter by CDX2 at the begin-
ning of the region that we investigated (3000 bp from the
TSS). This does not exclude the possibility of a genuine CDX2
binding site even upstream of the region investigated by us.
However, the fact that in our gain of function studies CDX2-
increased expression correlates mainly with FXR3/4 up-reg-
ulationwhen comparedwith FXR1/2 and the fact thatCDX2
binding sites are generally close to the TSS of its target genes (as
confirmed for FXR3/4) suggest that CDX2 might regulate
the expression of FXR1/2 in an indirect way. Alternatively,
the proximal regulatory site identified for FXR3/4 may also
act as a distant regulatory site for FXR1/2. Further studies
will be required to shed light on a possible downstream target of
CDX2 that would regulate the expression of FXR1/2.
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Combining our new results with what we previously pub-
lished (29), we can now speculate that, after inactivating muta-
tions of the APC gene, which is believed to be the primum
movens in the sequence from normal colonic mucosa to CRC,
FXR expression would be decreased, as a consequence of the
reduced expression and activity of the APC downstreammedi-
ator CDX2. In this scenario, a long term “Western style” diet
would produce high levels of toxic BAs that would not be buff-
ered by the detoxification activity of FXR and would be free to
further promote CRC via FXR-independent mechanisms. As a
result, a high fat diet would reduce the life span for the mani-
festation of CRC, contributing as one of the environmental fac-
tors responsible for the increased susceptibility to CRC
observed in the industrialized world. Finally, because it has
been also shown that BAs can induce CDX2 expression (50),
one could speculate that BA might stimulate their own detoxi-
fication in the intestine by inducing CDX2 expression, which
upon activation by APC would stimulate FXR expression that,
although promoting apoptosis, would induce the expression of
its target genes to induce BA detoxification. Thus, when
the APC-CDX2 axis is altered, as in the majority of CRC, the
reduced bile acid detoxification would account for the
increased risk of CRC development. This finding is concomi-
tantwith a report demonstrating thatCDX2 induces xenobiotic
metabolism enzyme genes in the intestine, an action that could
be mediated by FXR after induction by CDX2.
In conclusion, after becoming an adopted NR in 1999 with
the discovery of BAs as its endogenous ligands (22–24), herein
for the first time we provide evidence that CDX2 is the tran-
scriptional regulator of intestinal FXR. We believe that our
findings will provide the impetus to develop novel strategies
aiming at increasing intestinal FXR expression and activity to
prevent or delay high fat diet-related CRC development.
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